Series Recaps Biopharma, MedTech, and Science Trends and
Breakthroughs That Shaped the Year
LONDON, Jan. 16,
2025 /PRNewswire/ -- BioWorld™ published by Clarivate
Plc (NYSE:CLVT), a leading global provider of transformative
intelligence, has released its highly anticipated 2024 Year in
Review series. This multipart special report offers an in-depth
analysis of the therapeutic trends, regulatory actions and economic
shifts that defined biopharma, med tech and scientific innovation
over the past year while forecasting key developments for 2025.
As the biopharma and med-tech industries continue to evolve,
2024 proved to be a landmark year. The comprehensive recap by
BioWorld highlights therapeutic breakthroughs in psychiatry,
oncology, women's health and infectious diseases, alongside
economic highs and lows that challenged the global landscape. The
series also examines regulatory changes, including U.S. court cases
and international policy shifts, that could shape the future of
drug pricing, reimbursement, and innovation.
Lynn Yoffee, Publisher of
BioWorld, said: "The 2024 Year in Review series provides a
powerful lens into the transformative events and advancements that
shaped our industry this year. With our team of expert journalists
and analysts, we strive to distill complex developments into
actionable insights, empowering stakeholders to make informed
decisions as they navigate 2025 and beyond."
Key Highlights of the BioWorld 2024 Year in Review
Series:
BioWorld Year in Review: This section
highlights the top mergers and acquisitions, licensing deals,
financings, and first approvals of 2024. It also provides insights
into key therapeutic trends such as GLP-1 receptor agonists,
antibody-drug conjugates (ADCs), psychedelics, and the evolving
role of precision psychiatry, alongside innovations spurred by the
pandemic. Featured articles include:
- The Economy: Top Biopharma Trends of 2024 by Amanda
Lanier
A comprehensive infographic that highlights how 2024 showcased
resilience amidst challenges, with biopharma financing and deal
values rebounding significantly despite over 18,000 job losses and
a tempered IPO market. Spotlights include record-high deal values,
a steady M&A pace with reduced total value, and a slightly
increased rate of workforce reductions compared to 2023.
- Year's top US court cases to present new challenges for
2025 by Mari Serebrov
The Loper Bright decision ended the Chevron doctrine,
curbing agency authority and reshaping regulatory dynamics for
2025. Meanwhile, Gilead's $40 million
settlement over HIV drug delays highlights new liability risks for
biopharma. Both developments underscore the evolving legal
landscape and its potential to reshape regulatory and innovation
dynamics in 2025.
- European VC improves in 2024, driven by ADCs and CNS,
inflammatory drugs by Nuala
Moran
European biotech funding improved in 2024, with venture capital
raised exceeding 2020 levels but still trailing the pandemic peak.
Investors favored later-stage programs with clearer paths to exits,
while antibody-drug conjugates (ADCs) and central nervous system
(CNS) assets drew significant interest. Despite challenges like
closed public markets and antimicrobial fragility, optimism for
2025 is growing, fueled by expected macroeconomic improvements and
strong M&A activity.
- GLP-1 receptor agonists continue their global victory tour
by Anette Breindl
GLP-1 receptor agonists (GLP-1RAs) had a transformative 2024,
expanding into new therapeutic indications, including FDA approval
for treating obstructive sleep apnea in adults with obesity, while
continuing to demonstrate benefits in cardiovascular health, kidney
disease, and other conditions. Despite their success, GLP-1RAs
remain treatments rather than cures for underlying conditions like
diabetes, prompting ongoing research into root-cause
solutions.
BioWorld MedTech Year in Review: This section
recaps key med-tech and diagnostic breakthroughs, covering
cutting-edge advancements in brain mapping and pregnancy health, as
well as regulatory developments expected to impact the sector in
2025. Coverage includes:
- AI drives financings, approvals for APAC med-tech in
2024 By Marian (YoonJee) Chu
In 2024, AI spurred significant financings and approvals in APAC
med-tech, leveraging regional strengths like talent pools, data
infrastructure, and government support. Key highlights included
AI-powered IPOs, billion-dollar pharma collaborations, and national
investments, solidifying APAC's role in AI-driven healthcare
innovation.
- Medicare coverage issues abound in 2024 by Mark McCarty
In 2024, Medicare faced challenges in covering emerging
technologies, with the new TCET policy offering limited scope.
Coverage for digital health and SaaS remained stalled due to
outdated benefit categories. Meanwhile, Medicare's reimbursement
rates for radiation oncology and skin substitutes sparked
controversy.
BioWorld Science Year in Review: This section
explores key research milestones, featuring global collaborations
in infectious diseases, breakthroughs in curable tumors and
innovations in women's health and neuroscience. Key highlights
include:
- The map for a journey to the center of the brain by
Mar de Miguel
The year 2024 marks a milestone with
the end of a long journey: a complete cellular map of the fruit fly
brain, Drosophila melanogaster, and a cubic millimeter of
the human brain. The adventure is just beginning for the thinking
species Homo sapiens.
- Progress in cancer research, even the toughest types by
Mar de Miguel and Anette Breindl
Among the most profound results presented at the 2024 European
Society for Medical Oncology Congress were the 10-year data
from the Checkmate-067 and Keynote-006 trials, the phase III trials
that tested Opdivo (nivolumab, Bristol Myers Squibb Co.) and
Keytruda (pembrolizumab, Merck & Co. Inc.) as first-line agents
in advanced or metastatic melanoma.
The series also includes the BioWorld editorial picks for the
"Best of 2024," dynamic infographics summarizing key data, and a
global perspective on funding and policy changes across
Europe and Asia.
To access the full BioWorld special series,
visit https://www.bioworld.com/special_reports.
Join the conversation and mention BioWorld
on X and LinkedIn as well as Clarivate for Life
Sciences & Healthcare
on X and LinkedIn.
About BioWorld
With writers and editors stationed
around the globe, BioWorld published by Clarivate, reports the
breaking news - and provides key perspective on thousands of
therapeutics and devices in development, the companies behind those
candidates, the business development transactions that evolve the
markets, and the regulatory hurdles that both challenge and guard
the processes. BioWorld has a long tradition of excellence in
journalism. Collectively, the news services have been honored with
70 awards dating back to 1998.
About Clarivate
Clarivate™ is a leading global provider of transformative
intelligence. We offer enriched data, insights & analytics,
workflow solutions and expert services in the areas of Academia
& Government, Intellectual Property and Life Sciences &
Healthcare. For more information, please
visit www.Clarivate.com.
Media Contact:
Catherine
Daniel
Director, External Communications, Life Sciences &
Healthcare
newsroom@Clarivate.com
Logo -
https://mma.prnewswire.com/media/1159266/Clarivate_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/bioworld-by-clarivate-releases-comprehensive-2024-year-in-review-302352795.html
